The outcomes of mycophenolate mofetil therapy combined with systemic corticosteroids in acute uveitis associated with Vogt-Koyanagi-Harada disease

    loading  Checking for direct PDF access through Ovid

Abstract

Purpose:

To study the effectiveness of mycophenolate mofetil (MMF) as first-line therapy in acute uveitis associated with Vogt-Koyanagi-Harada (VKH) disease. The outcomes in this group were compared with those of another group of patients who were treated with corticosteroid monotherapy.

Methods:

19 patients(38 eyes) diagnosed with acute uveitis associated with VKH were included prospectively.

Results:

The mean follow-up period was 27.0±11.1 months. Corticosteroid-sparing effect was achieved in all patients. Ten patients discontinued treatment without relapse of inflammation. Visual acuity of 20/20 was achieved by 37.5% of the eyes in the corticosteroid group and by 73.7% in the corticosteroid + MMF group. Recurrent inflammation of 3 times or more was reduced significantly in the corticosteroid + MMF group as compared to corticosteroid group. Development of all complications was significantly higher in the corticosteroid group (42.6%) compared to the corticosteroid + MMF group (7.9%). None of the eyes in the corticosteroid + MMF group developed “sunset glow fundus”.

Conclusions:

Addition of MMF as first-line therapy to corticosteroids improves clinical outcomes in patients with acute uveitis associated with VKH disease.

Related Topics

    loading  Loading Related Articles